Design Therapeutics, Inc.
DSGN
$3.82
-$0.05-1.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 56.89% | 10.40% | -10.42% | -1.91% | -37.69% |
| Gross Profit | -56.89% | -10.40% | 10.42% | 1.91% | 37.69% |
| SG&A Expenses | 9.61% | 10.42% | -21.47% | -18.17% | -22.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.79% | 10.40% | -13.69% | -33.43% | -33.49% |
| Operating Income | -41.79% | -10.40% | 13.69% | 33.43% | 33.49% |
| Income Before Tax | -59.52% | -15.28% | 17.42% | 40.85% | 42.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.52% | -15.28% | 17.42% | 40.85% | 42.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.52% | -15.28% | 17.42% | 40.85% | 42.44% |
| EBIT | -41.79% | -10.40% | 13.69% | 33.43% | 33.49% |
| EBITDA | -42.10% | -10.43% | 13.87% | 33.70% | 33.76% |
| EPS Basic | -58.75% | -14.07% | 18.33% | 41.48% | 43.03% |
| Normalized Basic EPS | -58.75% | -14.02% | 18.38% | 41.49% | 43.02% |
| EPS Diluted | -58.75% | -14.07% | 18.33% | 41.48% | 43.03% |
| Normalized Diluted EPS | -58.75% | -14.02% | 18.38% | 41.49% | 43.02% |
| Average Basic Shares Outstanding | 0.48% | 1.05% | 1.13% | 1.08% | 1.04% |
| Average Diluted Shares Outstanding | 0.48% | 1.05% | 1.13% | 1.08% | 1.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |